Torsdag 26 December | 17:22:30 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-01-29 08:30 Bokslutskommuniké 2024
2024-11-08 - Extra Bolagsstämma 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-28 - Årsstämma
2024-05-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2022-01-18 - Extra Bolagsstämma 2022
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-28 - X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-06 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 - Årsstämma
2020-04-17 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-20 - Årsstämma
2019-05-10 - X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 - Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2023-06-02 12:10:00

Ziccum AB (publ) has appointed Johny Humaloja as its new CFO. Johny is a financial executive with decades of experience in the biopharma and biotech industries in Europe and the US. He will assume his new position on June 15. CEO Ann Gidner: “Johny’s profile is a perfect fit for us, as we keep moving forward. His appointment both contributes to and confirms our current international trajectory. We welcome him warmly”.

Johny Humaloja has extensive experience as a financial and controller executive in biopharma, biotech and medtech. He has served in senior positions in Europe and the US and is joining Ziccum from the position as CFO of Amniotics AB, where amongst other achievements he led the company through a successful IPO and listing on Nasdaq first north (in 2021). He will assume his new role at Ziccum on June 15th 2023.

Johny has an Executive MBA in Economics & Management from Lund University as well as a BSc in Business Administration & Economics. He brings extensive operational and industrial experience; he has served as a CFO, Financial and Logistics Director, Financial Control Director and as Plant Controller in the US of a large-scale biotech manufacturing facility with an annual budget of 110 MUSD. This is valuable additional expertise for Ziccum, which is taking its unique pharmaceutical drying technology LaminarPace forward to industrialization through international partnering by its licensing business model.

Johny’s appointment is part of the dynamic growth and development agenda at Ziccum. The company is currently also seeking to recruit a Chief Operating Officer, with international biopharma experience, as it continues to broaden and strengthen its strategic executive expertise. Ziccum’s current CFO, Frida Hjelmberg, will remain in the company for a good transition period.

CEO Ann Gidner: “I am delighted to welcome Johny to Ziccum. As we go forward driving partnered projects for licensing, a new team member with relevant, in-depth industry experience will be a great asset. I would like to thank Frida Hjelmberg for her dedicated work over the last few years. It has been a pleasure working with her. We look forward to having Johny onboard”.

Johny Humaloja: “this is a highly interesting opportunity and I’m very excited to join Ziccum, a true leader in its field with a unique technology and with significant potential. I look forward to helping the company realize that potential, moving Ziccum forward on its financial, operational, and transformational path, and driving an accelerated long-term growth journey”.